ファーマコビジランスの市場規模、シェア、動向分析レポート：製品ライフサイクル別、サービスプロバイダー別、タイプ別、治療領域別、プロセスフロー別、最終用途別、地域別、セグメント予測、2024年～2030年

ファーマコビジランス市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のファーマコビジランス市場規模は2030年までに117億8,000万米ドルに達すると予測されています。

2024年から2030年までのCAGRは6.8%で成長が見込まれています。市場成長の主な要因は、副作用（ADR）の発生率の増加です。ADRはヘルスケアシステムに大きな負担をかけ、先進国における罹患率の明らかな根拠の一つとなっています。米国国立生物工学情報センター（NCBI）によると、欧州では年間入院患者数の約20人に1人がADRに起因しています。ファーマコビジランス（PV）サービスは、医薬品に関連する悪影響を認識する際にメーカーを支援することで、臨床試験段階で重要な役割を果たしています。

さらに、2022年2月にJournal of Current Medicine Research and Practice誌に掲載された論文「Characterization of Seriousness and Outcome of Adverse Drug Reactions in Patients Receiving Cancer Chemotherapy Drugs-A Prospective Observational Study（がん化学療法薬を投与される患者における副作用の重大性と結果の特徴-前向き観察研究）」によると、米国では重篤なADRにより年間10万人以上が死亡しており、過去10年来、健康上の大きな懸念となっていることが明らかになった。致死的不整脈や肝不全などのADRは、医薬品の使用に関連するリスクが関連する利益を上回るため、医薬品の市場からの撤退につながる可能性があります。COVID-19の大流行は、PVサービス・プロバイダーにチャンスと課題の両方をもたらし、競争力を高めるための革新的なプラットフォームの開発につながった。

例えば、2020年12月、ライフサイエンス業界の商用サービスプロバイダーであるEVERSANAは、医薬品開発プロセスの自動化を専門とするライフサイエンス・ソフトウェア企業であるArisGlobalと提携しました。この提携は、エンド・ツー・エンドのPV手順をデジタル化し、より安全で効果的なヘルスケアを世界中で実現することを目的としています。クラウドベースのPVや医薬品安全性プラットフォームのように、技術的に先進的でユーザーフレンドリーなソフトウェアシステム市場は、予測期間中の業界の成長をサポートすると予想されます。例えば、Clinevo Technologiesは、症例処理、薬事申請/AS2ゲートウェイ、PVインテーク、アナリティクス、安全性シグナルなど様々な機能を網羅したクラウドベースのソリューション、Clinevo Safetyを提供しています。

このオールインワン・プラットフォームが市場を牽引しています。さらに、組織的な取り組みがブラジルのような新興市場の成長を支えています。例えば、ブラジルでは製薬業界、学界、臨床現場、保健当局が参加する患者安全・PVプログラムが導入されました。FIPFARMA（Fundacao Instituto de Pesquisas Farmaceuticas）とPharmacy College（Universidade de Sao Paulo）が提供するこのプログラムは、2つのコホート（2020年と2022年）で30時間のオンラインコースを実施しました。このコースでは、ヘルスケアとファーマコビジランスの概要、医薬品安全性と管理、患者安全文化などの重要なトピックを取り上げました。ワークショップでは、ヘルスケア専門家（HCP）が直面する実際の課題を取り上げ、共同での問題解決を促しました。

ビデオ会議は、HCPを効果的に関与させ、教育し、知識の共有を促進し、考え方の転換を促しました。このイニシアティブは参加者にポジティブな影響を与え、ブラジルにおけるPVの実践を強化しました。先進国の主な製薬企業は、コスト削減と運営費削減のためにPVサービスのアウトソーシングに注力しています。このため、発展途上国のCRO（医薬品開発業務受託機関）が業界シェアを拡大する機会が生まれると期待されます。メーカーは世界的に高まる患者ニーズを満たすため、製品開発手順の見直しを進めています。こうした要因により、PVサービスの需要は予測期間中に拡大すると予測されます。

さらに、PV業界各社は買収、提携、事業拡大、製品発表などの戦略を実施し、提供する製品の幅を広げ、市場での存在感を高めています。例えば、製薬業界に特化したサービスプロバイダーであるErgomed plcは、2022年2月にADAMAS Consulting Group Limitedを買収しました。ADAMASは医薬品製造、臨床試験監査、PVシステムの品質保証サービスを提供する国際的なコンサルタント会社です。今回の買収額は2,560万ポンド（英ポンド）で、エルゴメッド社の収益にプラスに働くことが期待されており、将来的にはさらなる成長と戦略的な優位性が見込まれています。

ファーマコビジランス市場レポートハイライト

• フェーズIVが2023年の収益シェア75.85%超で市場を席巻。これはADRインシデントの増加と市販後調査によるものです。
• 製薬企業がサービスのアウトソーシングにより業務コストの削減を目指したため、2023年のサービスプロバイダー分野の市場シェアは、アウトソーシング受託が60.63%を超えました。
• 自発報告型セグメントは2023年の売上高シェア30.22%超で市場をリードしました。その用途には、新規、重篤、希少なADRの効率的かつ費用対効果の高い検出が含まれます。
• 2023年の治療領域セグメントでは、慢性がん治療におけるバイオ製薬企業の研究努力に後押しされ、がん領域が26.95%超の最大シェアを占めました。
• 症例データ管理は、予測期間中、プロセスフロー分野で最も速いCAGR 7.3％で成長すると予測されます。
• 最終用途セグメントでは、バイオテクノロジー企業が最も速いCAGR 8.0％で成長すると予測されます。これは、生物製剤、治療薬、遺伝子治療などの新規製品の研究開発に注力しているためです。
• 北米は、新薬開発への投資、有利な規制、研究ユニットや臨床試験の強力なプレゼンスにより、2023年には32.55%を超える最大の売上シェアを占めました。
• 各社は競争優位を得るため、新製品の上市、提携、買収などの戦略を採用しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 ファーマコビジランス市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場分析
  • 補助市場分析
• 浸透と成長の見込みマッピング
• ファーマコビジランス市場力学
  • 市場 促進要因分析
  • 市場抑制要因分析
  • 業界の課題
• ファーマコビジランス市場分析ツール：ポーター
• SWOT分析、要因別（政治・法律、経済、技術）
• バリューチェーン分析
  • 前臨床
  • 臨床
  • PMA
• サービス提供とその需要に対するライフサイクルのマッピング
• 規制の枠組み
  • 国別規制機関一覧
• 組織構造のイントロダクション
• 価格モデル
  • 活動別の医薬品安全予算配分
  • 開発段階別
  • 治療領域別
  • 価格レベル
• 技術タイムラインの概要
  • 技術の変化と採用
• COVID-19の影響
  • 最近の動向と戦略的成果
  • 企業が実施する戦略
• 市場動向
  • リソースのスケーリング
  • ファーマコビジランスの自動化
• インフレの影響
• メディカルライティングと医療安全レビューの比較分析
  • 2022年のメディカルライティング市場の展望
  • 医療安全レビュー市場の展望、2022年

第4章 ファーマコビジランス市場：製品ライフサイクル別推定・動向分析

• 製品ライフサイクル別市場シェア分析、2022年および2030年
• 製品ライフサイクルダッシュボード
• 市場の定義と範囲

第5章 ファーマコビジランス市場：サービスプロバイダーの推定・動向分析

• サービスプロバイダー別市場シェア分析、2023年および2030年
• サービスプロバイダーダッシュボード
• 市場の定義と範囲

第6章 ファーマコビジランス市場：タイプ別推定・動向分析

• タイプ別市場シェア分析、2023年および2030年
• タイプダッシュボード
• 市場の定義と範囲

第7章 ファーマコビジランス市場：プロセスフロー別推定・動向分析

• プロセスフロー別市場シェア分析、2023年および2030年
• プロセスフローダッシュボード
• 市場の定義と範囲

第8章 ファーマコビジランス市場：治療領域別推定・動向分析

• 治療領域別市場シェア分析、2023年および2030年
• 治療領域ダッシュボード
• 市場の定義と範囲

第9章 ファーマコビジランス市場：最終用途別推定・動向分析

• 最終用途別市場シェア分析、2023年および2030年
• 最終用途ダッシュボード
• 市場の定義と範囲

第10章 ファーマコビジランス市場： 地域別推定・動向分析、製品、サービスプロバイダー、タイプ、最終用途別

• 地域別市場のスナップショット
• 北米
• 欧州
• アジア太平洋地域
• ラテンアメリカ
• 中東・アフリカ

第11章 ファーマコビジランス市場： 競合分析

• 市場参加の分類
• 公開会社
• 非公開会社
• 競合要因と戦略
• ファーマコビジランスサービスを利用するヘルスケア企業

第12章 競合情勢

• 企業プロファイル
  • ACCENTURE
  • CLINQUEST GROUP BV（LINICAL AMERICAS）
  • IQVIA Inc.
  • COGNIZANT
  • LABORATORY CORPORATION OF AMERICA HOLDINGS
  • IBM
  • ARISGLOBAL
  • ICON PLC.
  • CAPGEMINI
  • ITCLINICAL
  • TAKE SOLUTIONS LIMITED
  • PAREXEL INTERNATIONAL CORPORATION.
  • BIOCLINICA, INC.
  • WIPRO
  • UNITED BIOSOURCE LLC
  • FMD K&L（CLINCHOICE）

第13章 成功戦略

• 主な成功/スコアリング基準
  • カテゴリー別
• ベンダー選択の主要要素
  • カテゴリ別
  • 企業規模別

第14章 スイッチングコスト分析

List of Tables

• Table 1 List of secondary sources
• Table 2 List of Abbreviation
• Table 3 Types of ADRs
• Table 4 Adverse Drug Events (ADEs) in hospitals
• Table 5 Pharmacovigilance outsourcing services insights
• Table 6 List of regulations, by country
• Table 7 Estimated Total Per-Study Costs (in $ Millions), by Phase and Therapeutic Area
• Table 8 Case management costing by year
• Table 9 Price by case processing volume
• Table 10 Subscription services for medical manuscript writing
• Table 11 Total literature searches (2013-2022)
• Table 12 Instances of failed phase I clinical trials for COVID-19 vaccine
• Table 13 Recruiting phase II clinical trials for oncology
• Table 14 Outsourcing trend observed in pharmaceutical companies
• Table 15 Recent Market Events
• Table 16 List of Major Deals & Acquisitions
• Table 17 List of key distributors and channel partners
• Table 18 List of key emerging companies'/technology disruptors/innovators
• Table 19 North America Pharmacovigilance Market, by country, 2018 - 2030 (USD Million)
• Table 20 North America Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
• Table 21 North America Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
• Table 22 North America Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
• Table 23 U.S. Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
• Table 24 U.S. Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
• Table 25 U.S. Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
• Table 26 Canada Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
• Table 27 Canada Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
• Table 28 Canada Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
• Table 29 Europe Pharmacovigilance Market, by country, 2018 - 2030 (USD Million)
• Table 30 Europe Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
• Table 31 Europe Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
• Table 32 Europe Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
• Table 33 Germany Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
• Table 34 Germany Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
• Table 35 Germany Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
• Table 36 UK Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
• Table 37 UK Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
• Table 38 UK Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
• Table 39 France Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
• Table 40 France Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
• Table 41 France Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
• Table 42 Italy Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
• Table 43 Italy Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
• Table 44 Italy Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
• Table 45 Spain Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
• Table 46 Spain Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
• Table 47 Sapin Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
• Table 48 Denmark Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
• Table 49 Denmark Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
• Table 50 Denmark Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
• Table 51 Sweden Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
• Table 52 Sweden Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
• Table 53 Sweden Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
• Table 54 Norway Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
• Table 55 Norway Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
• Table 56 Norway Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
• Table 57 Asia Pacific Pharmacovigilance Market, by country, 2018 - 2030 (USD Million)
• Table 58 Asia Pacific Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
• Table 59 Asia Pacific Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
• Table 60 Asia Pacific Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
• Table 61 Japan Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
• Table 62 Japan Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
• Table 63 Japan Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
• Table 64 China Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
• Table 65 China Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
• Table 66 China Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
• Table 67 India Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
• Table 68 India Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
• Table 69 India Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
• Table 70 Australia Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
• Table 71 Australia Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
• Table 72 Australia Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
• Table 73 South Korea Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
• Table 74 Thailand Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
• Table 75 Thailand Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
• Table 76 Thailand Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
• Table 77 Latin America Pharmacovigilance Market, by country, 2018 - 2030 (USD Million)
• Table 78 Latin America Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
• Table 79 Latin America Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
• Table 80 Latin America Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
• Table 81 Brazil Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
• Table 82 Brazil Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
• Table 83 Brazil Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
• Table 84 Mexico Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
• Table 85 Mexico Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
• Table 86 Mexico Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
• Table 87 Argentina Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
• Table 88 Argentina Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
• Table 89 Argentina Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
• Table 90 MEA Pharmacovigilance Market, by country, 2018 - 2030 (USD Million)
• Table 91 MEA Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
• Table 92 MEA Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
• Table 93 MEA Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
• Table 94 South Africa Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
• Table 95 South Africa Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
• Table 96 South Africa Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
• Table 97 Saudi Arabia Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
• Table 98 Saudi Arabia Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
• Table 99 Saudi Arabia Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
• Table 100 UAE Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
• Table 101 UAE Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
• Table 102 UAE Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)
• Table 103 Kuwait Pharmacovigilance Market, by Injection Type, 2018 - 2030 (USD Million)
• Table 104 Kuwait Pharmacovigilance Market, by Anatomy, 2018 - 2030 (USD Million)
• Table 105 Kuwait Pharmacovigilance Market, by End Use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Pharmacovigilance market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Primary interviews in North America
• Fig. 6 Primary interviews in Europe
• Fig. 7 Primary interviews in APAC
• Fig. 8 Primary interviews in Latin America
• Fig. 9 Primary interviews in MEA
• Fig. 10 Market research approaches
• Fig. 11 Value-chain-based sizing & forecasting
• Fig. 12 QFD modeling for market share assessment
• Fig. 13 Market formulation & validation
• Fig. 14 Timeline of pharmacovigilance for a drug from development (premarket to post marketing)
• Fig. 15 Market Snapshot
• Fig. 16 Segment Snapshot (Product Life Cycle & Service Provider)
• Fig. 17 Segment Snapshot (Type & Therapeutic Area)
• Fig. 18 Segment Snapshot (Process Flow & End Use))
• Fig. 19 Competitive Landscape Snapshot
• Fig. 20 Penetration & growth prospect mapping
• Fig. 21 Pharmacovigilance market dynamics
• Fig. 22 Porter's five force model
• Fig. 23 Pharmacovigilance - SWOT analysis, by factor (political & legal, economic, and technological)
• Fig. 24 Pharmacovigilance & Patient Safety Services - Product Life Cycle
• Fig. 25 PV department
• Fig. 26 PV organization structure
• Fig. 27 Estimated budget allocation of drug safety activities at global and country-level
• Fig. 28 Comparison between estimated global and country-level drug safety budget allocation
• Fig. 29 Average % of drug safety budget contributed by function at a global level
• Fig. 30 Pharmacovigilance system cost for small-sized firms and larger-sized firms
• Fig. 31 Clinical trial cost by phase (%)
• Fig. 32 Selected clinical trials costs based on technology
• Fig. 33 Estimated cost of developing therapeutic medical device in the U.S.
• Fig. 34 The average monthly cost of illness due to ADRs
• Fig. 35 Medical Writers Employers by Industry
• Fig. 36 Trending topics on social media (2017)
• Fig. 37 ADR detection and from social media data
• Fig. 38 Common literature automation tool flow
• Fig. 39 Automation processes in PV
• Fig. 40 Deterrents to Leveraging the Cloud (Oracle Survey)
• Fig. 41 The three-step process to compute signal statistics from search log using big data
• Fig. 42 Risk Management Capacity &Capability with Pharmacovigilance Using Big Data
• Fig. 43 Pharma & Biotech R&D expense growth, 2020 (%)
• Fig. 44 Medical writing market outlook, 2022 (USD Million)
• Fig. 45 Medical writing market, 2018 - 2030 (USD Million)
• Fig. 46 Global medical safety review market, 2018 - 2030 (USD Million)
• Fig. 47 Pharmacovigilance market: Product life cycle movement analysis
• Fig. 48 Pharmacovigilance market product life cycle dashboard
• Fig. 49 Global Preclinical market, 2018 - 2030 (USD Million)
• Fig. 50 Global Phase I market, 2018 - 2030 (USD Million)
• Fig. 51 Global Phase II market, 2018 - 2030 (USD Million)
• Fig. 52 Global Phase III market, 2018 - 2030 (USD Million)
• Fig. 53 Adverse events reported in FAERS system, 2019 - 2022
• Fig. 54 Global Phase IV market, 2018 - 2030 (USD Million)
• Fig. 55 Pharmacovigilance market: Service provider movement analysis
• Fig. 56 Pharmacovigilance Service provider dashboard
• Fig. 57 Global In-house market, 2018 - 2030 (USD Million)
• Fig. 58 Global contract outsourcing market, 2018 - 2030 (USD Million)
• Fig. 59 Pharmacovigilance market: Type movement analysis
• Fig. 60 Pharmacovigilance type dashboard
• Fig. 61 Global spontaneous reporting market, 2018 - 2030 (USD Million)
• Fig. 62 Global intensified ADR reporting market, 2018 - 2030 (USD Million)
• Fig. 63 Global targeted spontaneous reporting market, 2018 - 2030 (USD Million)
• Fig. 64 Global CEM market, 2018 - 2030 (USD Million)
• Fig. 65 Global EHR mining market, 2018 - 2030 (USD Million)
• Fig. 66 Pharmacovigilance market: Process flow movement analysis
• Fig. 67 Pharmacovigilance market process flow dashboard
• Fig. 68 Global case data management market, 2018 - 2030 (USD Million)
• Fig. 69 Global case logging market, 2018 - 2030 (USD Million)
• Fig. 70 Global case data analysis market, 2018 - 2030 (USD Million)
• Fig. 71 Global medical reviewing and reporting market, 2018 - 2030 (USD Million)
• Fig. 72 Global signal detection market, 2018 - 2030 (USD Million)
• Fig. 73 Global adverse event logging market, 2018 - 2030 (USD Million)
• Fig. 74 Global adverse event analysis market, 2018 - 2030 (USD Million)
• Fig. 75 Global adverse event review & reporting market, 2018 - 2030 (USD Million)
• Fig. 76 Global risk management system market, 2018 - 2030 (USD Million)
• Fig. 77 Global Risk Evaluation System market, 2018 - 2030 (USD Million)
• Fig. 78 Global risk mitigation system market, 2018 - 2030 (USD Million)
• Fig. 79 Pharmacovigilance market: Therapeutic area movement analysis
• Fig. 80 Pharmacovigilance market therapeutic area dashboard
• Fig. 81 Global oncology market, 2018 - 2030 (USD Million)
• Fig. 82 Global neurology market, 2018 - 2030 (USD Million)
• Fig. 83 Global cardiology market, 2018 - 2030 (USD Million)
• Fig. 84 Global respiratory systems market, 2018 - 2030 (USD Million)
• Fig. 85 Global others market, 2018 - 2030 (USD Million)
• Fig. 86 Pharmacovigilance market: End use movement analysis
• Fig. 87 Pharmacovigilance market end use dashboard
• Fig. 88 Global pharmaceuticals market, 2018 - 2030 (USD Million)
• Fig. 89 Global biotechnology companies' market, 2018 - 2030 (USD Million)
• Fig. 90 Global medical device manufacturers market, 2018 - 2030 (USD Million)
• Fig. 91 Global others market, 2018 - 2030 (USD Million)
• Fig. 92 Regional market place: Key takeaways
• Fig. 93 North America pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 94 U.S. key country dynamics (Part 1)
• Fig. 95 U.S. key country dynamics (Part 2)
• Fig. 96 U.S. pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 97 Canada key country dynamics (Part 1)
• Fig. 98 Canada key country dynamics (Part 2)
• Fig. 99 Canada pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 100 Europe pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 101 UK key country dynamics (Part 1)
• Fig. 102 UK key country dynamics (Part 2)
• Fig. 103 UK pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 104 Germany key country dynamics (Part 1)
• Fig. 105 Germany key country dynamics (Part 2)
• Fig. 106 Germany pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 107 France key country dynamics (Part 1)
• Fig. 108 France key country dynamics (Part 2)
• Fig. 109 France pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 110 Italy key country dynamics (Part 1)
• Fig. 111 Italy key country dynamics (Part 2)
• Fig. 112 Italy pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 113 Spain key country dynamics (Part 1)
• Fig. 114 Spain key country dynamics (Part 2)
• Fig. 115 Spain pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 116 Russia key country dynamics
• Fig. 117 Russia pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 118 Denmark key country dynamics (Part 1)
• Fig. 119 Denmark key country dynamics (Part 2)
• Fig. 120 Denmark pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 121 Norway key country dynamics (Part 1)
• Fig. 122 Norway key country dynamics (Part 2)
• Fig. 123 Norway pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 124 Sweden key country dynamics (Part 1)
• Fig. 125 Sweden key country dynamics (Part 2)
• Fig. 126 Sweden pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 127 Asia Pacific Pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 128 Japan pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 129 China key country dynamics (Part 1)
• Fig. 130 China key country dynamics (Part 2)
• Fig. 131 China pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 132 India key country dynamics (Part 1)
• Fig. 133 India key country dynamics (Part 2)
• Fig. 134 India pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 135 Australia pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 136 Thailand key country dynamics (Part 1)
• Fig. 137 Thailand key country dynamics (Part 2)
• Fig. 138 Thailand pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 139 South Korea pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 140 Latin America pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 141 Brazil pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 142 Mexico key country dynamics
• Fig. 143 Mexico pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 144 Argentina pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 145 MEA pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 146 South Africa pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 147 Saudi Arabia pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 148 UAE key country dynamics (Part 1)
• Fig. 149 UAE key country dynamics (Part 2)
• Fig. 150 UAE pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 151 Kuwait pharmacovigilance market, 2018 - 2030 (USD Million)
• Fig. 152 Market participant categorization
• Fig. 153 Company market position analysis
• Fig. 154 Estimated company market share analysis, 2022 (%)
• Fig. 155 SWOT - Accenture
• Fig. 156 SWOT - Linical Americas
• Fig. 157 SWOT - IQVIA
• Fig. 158 SWOT - Cognizant
• Fig. 159 SWOT - Laboratory Corporation of America Holdings
• Fig. 160 SWOT - IBM Corporation
• Fig. 161 SWOT - ArisGlobal
• Fig. 162 SWOT - ICON plc
• Fig. 163 SWOT - Capgemini
• Fig. 164 SWOT - ITClinical
• Fig. 165 SWOT - Take Solutions
• Fig. 166 SWOT - Parexel International Corporation
• Fig. 167 SWOT - Clario
• Fig. 168 SWOT - Wipro
• Fig. 169 SWOT - United BioSource LLC
• Fig. 170 SWOT - FMD K&L
• Fig. 171 Commonly outsourced PV activities
• Fig. 172 Vendor selection criteria

Pharmacovigilance Market Growth & Trends:

The global pharmacovigilance market size is projected to reach USD 11.78 billion by 2030, according to a new report by Grand View Research, Inc. It is anticipated to witness growth at a CAGR of 6.8% from 2024 to 2030. The key factor responsible for the market growth is the growing incidence of Adverse Drug Reactions (ADR). ADR imposes a significant load on healthcare systems and is one of the evident grounds for morbidity in developed nations. As per the National Center for Biotechnology Information (NCBI), about 1 in 20 hospitalizations in Europe yearly are owing to ADR. Pharmacovigilance (PV) services play a vital role in the clinical trial phase by aiding manufacturers in recognizing the negative consequences associated with the drug.

Furthermore, a February 2022 article published in the Journal of Current Medicine Research and Practice titled "Characterization of Seriousness and Outcome of Adverse Drug Reactions in Patients Receiving Cancer Chemotherapy Drugs - A Prospective Observational Study" revealed that serious ADRs in the U.S. result in over 100,000 deaths annually and have been a major health concern since the past decade. ADRs, such as fatal arrhythmia and liver failure, can result in drug withdrawal from the market as the risks related to the drug usage outweigh its associated benefits. The COVID-19 pandemic presented both opportunities and challenges for PV service providers, leading to the development of innovative platforms for a competitive edge.

For instance, in December 2020, EVERSANA, a commercial services provider in the life sciences industry, collaborated with ArisGlobal, a life sciences software company specializing in automating drug development processes. This partnership was aimed to digitally transform end-to-end PV procedures, ensuring safer and more effective healthcare worldwide. The market for technologically advanced and user-friendly software systems, like cloud-based PV and drug safety platforms, is anticipated to support industry growth over the forecast period. For instance, Clinevo Technologies offers Clinevo Safety, a cloud-based solution encompassing various functionalities, such as Case Processing, Regulatory Submissions/AS2 Gateway, PV Intake, Analytics, and Safety Signals.

This all-in-one platform is driving the market forward. Furthermore, organizational initiatives support the growth of emerging markets like Brazil. For instance, a collaborative Patient Safety and PV program was introduced in Brazil, involving the pharmaceutical industry, academia, clinical practice, and health authorities. Offered by FIPFARMA (Fundacao Instituto de Pesquisas Farmaceuticas) and Pharmacy College (Universidade de Sao Paulo), the program conducted a 30-hour online course in two cohorts (2020 and 2022). It covered crucial topics, such as Healthcare and Pharmacovigilance Overview, Drug Safety & Management, and Patient Safety Culture. Workshops addressed real Challenges Healthcare Professionals (HCPs) faced and encouraged collaborative problem-solving.

Video conferences effectively engaged and educated HCPs, facilitating knowledge sharing and promoting a mindset shift. This initiative positively impacted participants and enhanced PV practices in Brazil. Key pharma companies in developed nations are concentrating on outsourcing PV services to decrease costs and reduce operational expenses. This is expected to create an opportunity for Contact Research Organizations (CROs) in developing territories to acquire more industry share. Manufacturers are renovating their product development procedures to fulfill the growing patient needs worldwide. These factors are predicted to augment the demand for PV services over the forecast period.

Furthermore, PV industry players are implementing strategies like acquisitions, collaborations, expansions, and product launches to broaden their offerings and expand their market presence. For example, in February 2022, Ergomed plc, a specialized services provider to the pharmaceutical industry, acquired ADAMAS Consulting Group Limited. ADAMAS is an international consultancy that offers quality assurance services in pharmaceutical manufacturing, clinical trial auditing, and PV systems. The acquisition, valued at £25.6 million (in pounds), is expected to favor Ergomed's earnings, with further growth and strategic advantages anticipated in the future.

Pharmacovigilance Market Report Highlights:

• Phase IV dominated the market with a revenue share of over 75.85% in 2023. This was driven by increased ADR incidents and post-marketing surveillance
• Contract outsourcing accounted for over 60.63% market share in the service provider segment in 2023, as pharmaceutical organizations aimed to reduce operational costs by outsourcing services
• The spontaneous reporting type segment led the market with a revenue share of over 30.22% in 2023. Its applications include efficient and cost-effective detection of new, serious, and rare ADRs
• Oncology held the largest share of over 26.95% in the therapeutic area segment in 2023, fueled by biopharmaceutical companies' research efforts in chronic cancer treatments
• Case data management is anticipated to grow at the fastest CAGR of 7.3% in the process flow segment during the forecast period
• Biotechnology companies are expected to have the fastest CAGR of 8.0% in the end-use segment. This is due to their focus on R&D for novel products, such as biologics, therapies, and gene therapies
• North America held the largest revenue share of over 32.55% in 2023 due to investments in new drug development, favorable regulations, and a strong presence of research units and clinical trials
• Companies are adopting strategies like new product launches, collaborations, and acquisitions to gain a competitive advantage

Table of Contents

Chapter 1 Research Methodology & Scope

• 1.1 Market Segmentation & Scope
  • 1.1.1 Product Life Cycle
  • 1.1.2 Service Provider
  • 1.1.3 Type
  • 1.1.4 Process Flow
  • 1.1.5 Therapeutic Area
  • 1.1.6 End Use
  • 1.1.7 Regional Scope
  • 1.1.8 Estimates and Forecast Timeline
• 1.2 Research Methodology
• 1.3 Information Procurement
  • 1.3.1 Purchased Database:
  • 1.3.2 GVR's Internal Database
  • 1.3.3 Secondary Sources
  • 1.3.4 Primary Research:
  • 1.3.5 Details Of Primary Research
    • 1.3.5.1 Data for primary interviews in North America
    • 1.3.5.2 Data for Primary Interviews in Europe
    • 1.3.5.3 Data for Primary Interviews in Asia Pacific
    • 1.3.5.4 Data for Primary Interviews in Latin America
    • 1.3.5.5 Data for Primary Interviews in Middle East & Africa
• 1.4 Information or Data Analysis
  • 1.4.1 Data Analysis Models
• 1.5 Market Formulation & Validation
• 1.6 Model Details
  • 1.6.1 Commodity Flow Analysis
    • 1.6.1.1 Top down market estimation
    • 1.6.1.2 CAGR Calculation
    • 1.6.1.3 Key Report Updates
• 1.7 List of Secondary Sources
• 1.8 List of Abbreviations
• 1.9 Market Definitions
• 1.10 Report Objectives
  • 1.10.1 Objective 1:
  • 1.10.2 Objective 2:

Chapter 2 Executive Summary

• 2.1 Market Snapshot
• 2.2 Segment Snapshot (Product Life Cycle & Service Provider)
• 2.3 Segment Snapshot (Type & Therapeutic Area)
• 2.4 Segment Snapshot (Process Flow & End Use)
• 2.5 Competitive Landscape Snapshot

Chapter 3 Pharmacovigilance Market Variables, Trends & Scope

• 3.1 Market Lineage Outlook
  • 3.1.1 Parent Market Analysis
  • 3.1.2 Ancillary Market Analysis
• 3.2 Penetration & Growth Prospect Mapping
• 3.3 Pharmacovigilance Market Dynamics
  • 3.3.1 Market Driver Analysis
    • 3.3.1.1 Growing drug consumption and drug development rates
    • 3.3.1.2 Increasing incidence of ADR and drug toxicity
    • 3.3.1.3 Increasing trend of outsourcing pharmacovigilance services
    • 3.3.1.4 Increasing externalization of clinical trial studies by large pharmaceutical and biopharmaceutical companies
    • 3.3.1.5 Increasing regulatory Burden on Manufacturers
    • 3.3.1.6 Introduction of technologically advanced software services
    • 3.3.1.7 Constantly rising investment on R&D by healthcare companies
    • 3.3.1.8 Partnerships and collaborations between market players
  • 3.3.2 Market Restraint Analysis
    • 3.3.2.1 Shortage of skilled labor
    • 3.3.2.2 Expensive technology for small and mid-sized player
    • 3.3.2.3 Lack of recognition
    • 3.3.2.4 Scarcity of integration standards
  • 3.3.3 Industry Challenges
• 3.4 Pharmacovigilance Market Analysis Tools: Porters
• 3.5 SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
• 3.6 Value Chain Analysis
  • 3.6.1 Preclinical
  • 3.6.2 Clinical
  • 3.6.3 PMA
• 3.7 Mapping of Life Cycle against Service Offering and Their Demand
• 3.8 Regulatory Framework
  • 3.8.1 List of Regulatory Bodies by Country
• 3.9 Organization Structure Introduction
• 3.10 Pricing Models
  • 3.10.1 Drug Safety Budget Allocation by Activities
  • 3.10.2 By Development Phase
  • 3.10.3 By Therapeutic Area
  • 3.10.4 Pricing Level
    • 3.10.4.1 Project management
    • 3.10.4.2 Case processing
    • 3.10.4.3 ADR Reporting
    • 3.10.4.4 Medical writing
    • 3.10.4.5 Drug safety management
• 3.11 Technology Timeline Overview
  • 3.11.1 Changing Technology & Adoption
    • 3.11.1.1 Social Media
    • 3.11.1.2 Literature screening
    • 3.11.1.3 Automation and AI
    • 3.11.1.4 Big data analytics in PV
• 3.12 Impact of COVID-19
  • 3.12.1 Recent Developments & Strategic Outcomes
    • 3.12.1.1 Regulatory requirements/changes due to covid-19
  • 3.12.2 Strategies Implemented by Companies
    • 3.12.2.1 IQVIA
    • 3.12.2.2 PARAXEL International Corporation
    • 3.12.2.3 Bioclinica
    • 3.12.2.4 Pharmaceutical Product Development (PPD)
    • 3.12.2.5 IBM Corporation
    • 3.12.2.6 ICON, plc
    • 3.12.2.7 PRA Health Sciences
    • 3.12.2.8 Covance Inc.
    • 3.12.2.9 ArisGlobal
    • 3.12.2.10 Linical Accelovance
    • 3.12.2.11 Laboratory Corporation of America Holdings
• 3.13 Market Trends
  • 3.13.1 Scaling Of Resources
  • 3.13.2 Automation in Pharmacovigilance
• 3.14 Impact of Inflation
• 3.15 Comparative Analysis between Medical Writing vs Medical Safety Review
  • 3.15.1 Medical Writing Market Outlook, 2022
    • 3.15.1.1 Medical writing Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 3.15.2 Medical Safety Review Market Outlook, 2022
    • 3.15.2.1 Medical Safety Review market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 4 Pharmacovigilance Market: Product Life Cycle Estimates & Trend Analysis

• 4.1 Product Life Cycle Market Share Analysis, 2022 & 2030
• 4.2 Product Life Cycle Dashboard
• 4.3 Market definition and scope
  • 4.3.1 Preclinical
    • 4.3.1.1 Preclinical market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.3.2 Phase I
    • 4.3.2.1 Phase I market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.3.3 Phase II
    • 4.3.3.1 Phase II market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.3.4 Phase III
    • 4.3.4.1 Phase III market estimates and forecasts, 2018 - 2030 (USD Million)
  • 4.3.5 Phase IV
    • 4.3.5.1 Phase IV market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5 Pharmacovigilance Market: Service Provider Estimates & Trend Analysis

• 5.1 Service provider Market Share Analysis, 2023 & 2030
• 5.2 Service Provider Dashboard
• 5.3 Market definition and scope
  • 5.3.1 IN HOUSE
    • 5.3.1.1 In house market estimates and forecasts, 2018 - 2030 (USD Million)
  • 5.3.2 Contract Outsourcing
    • 5.3.2.1 Contract outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6 Pharmacovigilance Market: Type Estimates & Trend Analysis

• 6.1 Type Market Share Analysis, 2023 & 2030
• 6.2 Type Dashboard
• 6.3 Market definition and scope
  • 6.3.1 Spontaneous Reporting
    • 6.3.1.1 Spontaneous Reporting market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.3.2 Intensified ADR Reporting
    • 6.3.2.1 Intensified ADR Reporting market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.3.3 Targeted Spontaneous Reporting
    • 6.3.3.1 Targeted spontaneous reporting market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.3.4 Cohort Event Monitoring (CEM)
    • 6.3.4.1 CEM market estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.3.5 EHR Mining
    • 6.3.5.1 EHR Mining market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7 Pharmacovigilance Market: Process Flow Estimates & Trend Analysis

• 7.1 Process Flow Market Share Analysis, 2023 & 2030
• 7.2 Process Flow Dashboard
• 7.3 Market definition and scope
  • 7.3.1 Case Data Management
    • 7.3.1.1 Case data management market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.3.1.1.1 Case logging
    • 7.3.1.1.1.1 Case logging market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.3.1.1.2 Case data analysis
    • 7.3.1.1.2.1 Case data analysis market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.3.1.1.3 Medical reviewing and reporting
    • 7.3.1.1.3.1 Medical reviewing and reporting market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.3.2 Signal Detection
    • 7.3.2.1 Signal detection market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.3.2.1.1 Adverse event logging
    • 7.3.2.1.1.1 Adverse Event Logging market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.3.2.1.2 Adverse Event Analysis
    • 7.3.2.1.2.1 Adverse Event Analysis market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.3.2.1.3 Adverse Event Review & Reporting
    • 7.3.2.1.3.1 Adverse Event Review & Reporting market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.3.3 Risk Management System
    • 7.3.3.1 Risk Management System market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.3.3.1.1 Risk Evaluation System
    • 7.3.3.1.1.1 Risk Evaluation System market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.3.3.1.2 Risk Mitigation System
    • 7.3.2.1.2.1 Risk Mitigation System market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 8 Pharmacovigilance Market: Therapeutic Area Estimates & Trend Analysis

• 8.1 Therapeutic Area Market Share Analysis, 2023 & 2030
• 8.2 Therapeutic Area Dashboard
• 8.3 Market definition and scope
  • 8.3.1 Oncology
    • 8.3.1.1 Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.3.2 Neurology
    • 8.3.2.1 Neurology market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.3.3 Cardiology
    • 8.3.3.1 Cardiology market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.3.4 Respiratory Systems
    • 8.3.4.1 Respiratory systems market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.3.5 Others
    • 8.3.5.1 Others market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 9 Pharmacovigilance Market: End Use Estimates & Trend Analysis

• 9.1 End Use Market Share Analysis, 2023 & 2030
• 9.2 End Use Dashboard
• 9.3 Market definition and scope
  • 9.3.1 Pharmaceuticals
    • 9.3.1.1 Pharmaceuticals market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.3.2 Biotechnology Companies
    • 9.3.2.1 Biotechnology companies market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.3.3 Medical Device Manufacturers
    • 9.3.3.1 Medical Device Manufacturers market estimates and forecasts, 2018 - 2030 (USD Million)
  • 9.3.4 Others
    • 9.3.4.1 Others market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 10 Pharmacovigilance Market: Regional Estimates & Trend Analysis, By, Product, Service Providers, Type, and End Use

• 10.1 Regional Market Snapshot
• 10.2 North America
  • 10.2.1 North America Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.2.2 U.S.
    • 10.2.2.1 U.S. Pharmacovigilance market estimates and forecasts, 2018- 2030 (USD Million)
    • 10.2.2.2 Competitive scenario
    • 10.2.2.3 Regulatory Framework
  • 10.2.3 Canada
    • 10.2.3.1 Canada Pharmacovigilance market estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.2.3.2 Competitive scenario
    • 10.2.3.3 Regulatory Framework
• 10.3 Europe
  • 10.3.1 Europe Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.3.2 UK
    • 10.3.2.1 UK Pharmacovigilance market estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.3.2.2 Competitive scenario
    • 10.3.2.3 Regulatory Framework
  • 10.3.3 Germany
    • 10.3.3.1 Germany Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million
    • 10.3.3.2 Competitive scenario
    • 10.3.3.3 Regulatory Framework
  • 10.3.4 France
    • 10.3.4.1 France Pharmacovigilance market estimates and forecasts, 2018- 2030 (USD Million)
    • 10.3.4.2 Competitive scenario
    • 10.3.4.3 Regulatory Framework
  • 10.3.5 Italy
    • 10.3.5.1 Italy Pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
    • 10.3.5.2 Competitive scenario
    • 10.3.5.3 Regulatory Framework
  • 10.3.6 Spain
    • 10.3.6.1 Spain pharmacovigilance market estimates and forecasts, 2018 - 2030 (USD Million)
    • 10.3.6.2 Competitive scenario
    • 10.3.6.3 Regulatory Framework
  • 10.3.7 Russia
    • 10.3.7.1 Russia Pharmacovigilance market estimates and forecasts, 2018- 2030 (USD Million)
    • 10.3.7.2 Competitive scenario
    • 10.3.7.3 Regulatory Framework
  • 10.3.8 Denmark
    • 10.3.8.1 Denmark Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.3.8.2 Competitive scenario
    • 10.3.8.3 Regulatory Framework
  • 10.3.9 Norway
    • 10.3.9.1 Norway Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.3.9.2 Competitive scenario
    • 10.3.9.3 Regulatory Framework
  • 10.3.10 Sweden
    • 10.3.10.1 Sweden Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.3.10.2 Competitive scenario
    • 10.3.10.3 Regulatory Framework
• 10.4 Asia Pacific
  • 10.4.1 Asia Pacific Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.4.2 JAPAN
    • 10.4.2.1 Japan Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.4.2.2 Competitive scenario
    • 10.4.2.3 Regulatory Framework
  • 10.4.3 CHINA
    • 10.4.3.1 China Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.4.3.2 Competitive Scenario
    • 10.4.3.3 Regulatory Framework
  • 10.4.4 India
    • 10.4.4.1 India Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.4.4.2 Competitive Scenario
    • 10.4.4.3 Regulatory Framework
  • 10.4.5 Australia
    • 10.4.5.1 Australia Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.4.5.2 Competitive Scenario
    • 10.4.5.3 Regulatory Framework
  • 10.4.6 Thailand
    • 10.4.6.1 Thailand Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.4.6.2 Competitive Scenario
    • 10.4.6.3 Regulatory Framework
  • 10.4.7 South Korea
    • 10.4.7.1 South Korea Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.4.7.2 Competitive Scenario
    • 10.4.7.3 Regulatory Framework
• 10.5 Latin America
  • 10.5.1 Latin America Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.5.2 Brazil
    • 10.5.2.1 Brazil Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.5.2.2 Competitive Scenario
    • 10.5.2.3 Regulatory Framework
  • 10.5.3 Mexico
    • 10.5.3.1 Mexico Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.5.3.2 Competitive Scenario
    • 10.5.3.3 Regulatory Framework
  • 10.5.4 Argentina
    • 10.5.4.1 Argentina Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.5.4.2 Competitive Scenario
    • 10.5.4.3 Regulatory Framework
• 10.6 MEA
  • 10.6.1 MEA Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 10.6.2 South Africa
    • 10.6.2.1 South Africa Pharmacovigilance Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 10.6.2.2 Competitive Scenario
    • 10.6.2.3 Regulatory Framework
  • 10.6.3 Saudi Arabia
    • 10.6.3.1 Saudi Arabia Pharmacovigilance Market Estimates and Forecasts, 2018- 2030 (USD Million)
    • 10.6.3.2 Competitive Scenario
    • 10.6.3.3 Regulatory Framework
  • 10.6.4 UAE
    • 10.6.4.1 UAE Arabia Pharmacovigilance Market Estimates and Forecasts, 2018- 2030 (USD Million)
    • 10.6.4.2 Competitive Scenario
    • 10.6.4.3 Regulatory Framework
  • 10.6.5 Kuwait
    • 10.6.5.1 Kuwait Pharmacovigilance Market Estimates and Forecasts, 2018- 2030 (USD Million)
    • 10.6.5.2 Competitive Scenario
    • 10.6.5.3 Regulatory Framework

Chapter 11 Pharmacovigilance Market: Competitive Analysis

• 11.1 Market Participation Categorization
• 11.2 Public Companies
  • 11.2.1 Company Market Position Analysis
  • 11.2.2 Company Market Share
• 11.3 Private Companies
  • 11.3.1 List of Key Emerging Companies
• 11.4 Competitive Factors and Strategies
  • 11.4.1 Increasing strategic collaborations and product launch
  • 11.4.2 Strategic Government initiatives which include collaborations
  • 11.4.3 Competitors increased PV awareness program
  • 11.4.4 Competitors increased collaboration and outsourcing of operations
  • 11.4.5 Consolidation Trends
• 11.5 Healthcare Companies Using Pharmacovigilance Services
  • 11.5.1 Potential Customers
  • 11.5.2 Notable Cases
    • 11.5.2.1 Case Study 1
    • 11.5.2.1.1 Case Study 1
    • 11.5.3.1.2 Case Study 2
    • 11.5.2.2 Case Study 2
    • 11.5.2.3 Case Study 3
    • 11.5.3.4 Case Study 4
  • 11.5.3 Key Focus areas for the pharmaceutical/healthcare companies
    • 11.5.3.1 Adoption of technological advancements in life sciences industry
    • 11.5.3.2 Published survey insights - related to adoption of pharmacovigilance automation

Chapter 12 Competitive Landscape

• 12.1 Company Profiles
  • 12.1.1 ACCENTURE
    • 12.1.1.1 Company overview
    • 12.1.1.2 Service benchmarking
    • 12.1.1.3 Financial performance
    • 12.1.1.4 Strategic initiatives
    • 12.1.1.5 SWOT Analysis
  • 12.1.2 CLINQUEST GROUP B.V. (LINICAL AMERICAS)
    • 12.1.2.1 Company overview
    • 12.1.2.2 Service benchmarking
    • 12.1.2.3 Financial performance
    • 12.1.2.4 Strategic initiatives
    • 12.1.2.5 SWOT Analysis
  • 12.1.3 IQVIA Inc.
    • 12.1.3.1 Company overview
    • 12.1.3.2 Service benchmarking
    • 12.1.3.3 Financial performance
    • 12.1.3.4 Strategic initiatives
    • 12.1.3.5 SWOT Analysis
  • 12.1.4 COGNIZANT
    • 12.1.4.1 Company overview
    • 12.1.4.2 Service benchmarking
    • 12.1.4.3 Financial performance
    • 12.1.4.4 Strategic initiatives
    • 12.1.4.5 SWOT Analysis
  • 12.1.5 LABORATORY CORPORATION OF AMERICA HOLDINGS
    • 12.1.5.1 Company overview
    • 12.1.5.2 Service benchmarking
    • 12.1.5.3 Financial performance
    • 12.1.5.4 Strategic initiatives
    • 12.1.5.5 SWOT Analysis
  • 12.1.6 IBM
    • 12.1.6.1 Company overview
    • 12.1.6.2 Service benchmarking
    • 12.1.6.3 Financial performance
    • 12.1.6.4 Strategic initiatives
    • 12.1.6.5 SWOT Analysis
  • 12.1.7 ARISGLOBAL
    • 12.1.7.1 Company Overview
    • 12.1.7.2 Service Benchmarking
    • 12.1.7.3 Financial Performance
    • 12.1.7.4 Strategic Initiatives
    • 12.1.7.5 SWOT Analysis
  • 12.1.8 ICON PLC.
    • 12.1.8.1 Company Overview
    • 12.1.8.2 Service Benchmarking
    • 12.1.8.3 Financial Performance
    • 12.1.8.4 Strategic Initiatives
    • 12.1.8.5 SWOT Analysis
  • 12.1.9 CAPGEMINI
    • 12.1.9.1 Company Overview
    • 12.1.9.2 Service Benchmarking
    • 12.1.9.3 Financial Performance
    • 12.1.9.4 Strategic Initiatives
    • 12.1.9.5 SWOT Analysis
  • 12.1.10 ITCLINICAL
    • 12.1.10.1 Company Overview
    • 12.1.10.2 Service Benchmarking
    • 12.1.10.3 Financial Performance
    • 12.1.10.4 Strategic Initiatives
    • 12.1.10.5 SWOT Analysis
  • 12.1.11 TAKE SOLUTIONS LIMITED
    • 12.1.11.1 Company Overview
    • 12.1.11.2 Service Benchmarking
    • 12.1.11.3 Financial Performance
    • 12.1.11.4 Strategic Initiatives
    • 12.1.11.5 SWOT Analysis
  • 12.1.12 PAREXEL INTERNATIONAL CORPORATION.
    • 12.1.12.1 Company Overview
    • 12.1.12.2 Service Benchmarking
    • 12.1.12.3 Financial Performance
    • 12.1.12.4 Strategic Initiatives
    • 12.1.12.5 SWOT Analysis
  • 12.1.13 BIOCLINICA, INC.
    • 12.1.13.1 Company overview
    • 12.1.13.2 Service benchmarking
    • 12.1.13.3 Financial performance
    • 12.1.13.4 Strategic initiatives
    • 12.1.13.5 SWOT Analysis
  • 12.1.14 WIPRO
    • 12.1.14.1 Company Overview
    • 12.1.14.2 Service Benchmarking
    • 12.1.14.3 Financial Performance
    • 12.1.14.4 Strategic Initiatives
    • 12.1.14.5 SWOT Analysis
  • 12.1.15 UNITED BIOSOURCE LLC
    • 12.1.15.1 Company Overview
    • 12.1.15.2 Service Benchmarking
    • 12.1.15.3 Financial Performance
    • 12.1.15.4 Strategic initiatives
    • 12.1.15.5 SWOT Analysis
  • 12.1.16 FMD K&L (CLINCHOICE)
    • 12.1.16.1 Company Overview
    • 12.1.16.2 Service Benchmarking
    • 12.1.16.3 Financial performance
    • 12.1.16.4 Strategic initiatives
    • 12.1.16.5 SWOT Analysis

Chapter 13 Winning Strategies

• 13.1 Key Winning/Scoring Criteria
  • 13.1.1 By Categories
    • 13.1.1.1 Pharmaceuticals
    • 13.1.1.2 Biotech companies
    • 13.1.1.3 Medical device companies
• 13.2 Key Vendor Selection Factors
  • 13.2.1 By Category
  • 13.2.2 By Company Size
    • 13.2.2.1 Key Takeaways

Chapter 14 Switching Cost Analysis